The UK and US have reached a landmark bilateral deal that will guarantee zero import taxes on UK drug shipments going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise spending on medicines through the National Health Service (NHS). This move guarantees that duties on these crucial products will be held at nothing for a timeframe of the next three years.
This deal comes after earlier threats to hike duties on branded drug products, with potential rates discussed reaching one hundred percent.
"This agreement with the Britain reinforces the global environment for new treatments and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," an announcement noted.
Trade Impact
Medicines are one of the UK's most significant export categories to the US, which is by far the biggest buyer for large UK drugmakers.
Export figures reveal that in the year prior to the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This agreement protects jobs, increases funding and sets the stage for the UK to establish itself as a international leader for life sciences," a minister stated.
Specific NHS Changes
The agreement includes several notable commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to double overall health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be limited at 15%. Previously, rebates were more than 20%.
Broader Context
The pact takes place against a protracted row between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by arguments that American patients were paying significantly more for the same drugs than people in the other developed nations.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar investments have been directed toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a proportion of its total funding over the past decade.
